Biotech and specialty pharma companies at SABCS 2026
Dec 8–11, 2026 San Antonio, TX ~11k attendees Website
35 biotech and specialty pharma companies are at SABCS 2026 — 31 presentations on the program and 11 with a booth in the exhibit hall. Most represented: Greenwich LifeSciences (1 on the program), Celcuity (1 on the program). 11 of them have their own page in this guide. As of Nov 10, 2026.
Focus
Top represented
Showing 1–17 of 35 organizations
| Organization | SABCS 2026 Attendance |
|---|---|
Greenwich LifeSciences Stafford, TX | |
Clinical-stage biotech testing GP2, a HER2 peptide immunotherapy, in the Phase III Flamingo-01 trial to prevent breast cancer from returning. | Booth Exhibiting at Booth 809 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Celcuity Minneapolis, MN | |
Clinical-stage company developing gedatolisib, a PI3K/mTOR pathway inhibitor, for HR+/HER2- advanced breast cancer. | Booth Exhibiting at Booth 1510 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
BioNTech Mainz, Germany | |
Biotech company developing mRNA and other cancer immunotherapies and antibody-drug conjugates, including a HER2-directed ADC in breast cancer trials. | Booth Exhibiting at Booth 251 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Lantern Pharma Dallas, TX | |
Oncology drug developer using AI and genomics to speed discovery, with candidates for DNA-repair-deficient cancers including triple-negative breast cancer. | Booth Exhibiting at Booth 1153 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
LeonaBio Bothell, WA | |
Biotech developing therapies for metastatic breast cancer that no longer responds to treatment, and for ALS. | Booth Exhibiting at Booth 1431 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Olema Oncology San Francisco, CA | |
Clinical-stage company developing palazestrant, an oral estrogen receptor antagonist and degrader, in Phase 3 trials for ER+/HER2- advanced breast cancer. | Booth Exhibiting at Booth 1342 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Puma Biotechnology Los Angeles, CA | |
Markets NERLYNX (neratinib) for HER2-positive breast cancer and is testing alisertib with hormone therapy in HR+/HER2- metastatic breast cancer. | Booth Exhibiting at Booth 209 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Relay Therapeutics Cambridge, MA | |
Clinical-stage company combining computation and experiments to design small-molecule drugs, including a PI3Kα inhibitor for HR+/HER2- breast cancer. | Booth Exhibiting at Booth 1450 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
TerSera Therapeutics Deerfield, IL | |
Specialty biopharma company with oncology and rare-disease medicines, including goserelin (Zoladex) in the US. | Booth Exhibiting at Booth 808 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Corcept Therapeutics Redwood City, CA | |
Biopharma company developing cortisol-modulating medicines, including relacorilant, for endocrine disorders and cancers such as ovarian cancer. | Booth Exhibiting at Booth 1632 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Rigel Pharmaceuticals South San Francisco, CA | |
Commercial-stage biotech marketing medicines for hematology and cancer. | Booth Exhibiting at Booth 1311 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Atossa Therapeutics Seattle, WA | |
A clinical-stage biopharmaceutical company developing therapies for breast cancer. | Poster Wed Dec 9 12:30–2pm |
BT BriaCell Therapeutics Philadelphia, PA | |
A biotechnology company developing immunotherapies for cancer, including breast cancer. | Poster Fri Dec 11 12:30–2pm |
Sapu Bioscience San Diego, CA | |
An immuno-oncology company developing RNA therapeutics and small-molecule drugs for cancer and infectious diseases. | Poster Wed Dec 9 12:30–2pm |
AT Atheron Therapeutics Shanghai, China | |
A biotechnology company with research and development operations in Shanghai. | Poster Wed Dec 9 12:30–2pm |
Ajinomoto do Brasil São Paulo, Brazil | |
Brazilian subsidiary of Ajinomoto, developing food, nutrition and amino-acid solutions through its AminoScience research and business activities. | |
Aminex Therapeutics Kenmore, WA | |
Clinical-stage biotechnology company developing an investigational cancer immunotherapy for adult and pediatric cancers. | Poster Wed Dec 9 5–6:30pm |
Find buyers from biotech and specialty pharma companies
Tell us what you sell and we’ll find the people at these biotech and specialty pharma companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse SABCS 2026 by
Organization type
Focus
- Genomic and tumor testing 160
- Hormone receptor-positive breast cancer 157
- Triple-negative breast cancer 99
- Patient and family support 96
- Breast surgery and biopsy 93
- HER2-positive breast cancer 81
- Hereditary risk and genetic testing 64
- AI and data 60
- Clinical trials and research 58
- Metastatic breast cancer 54
- Side effects and supportive care 46
- Screening and early detection 39
- Liquid biopsy and MRD 11
Exhibit hall
Everyone
Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published program and exhibitor list. Submit a correction